Femasys CEO Meets with Members of Congress to Discuss Women’s Healthcare Landscape

Shares in Femasys Inc. (Nasdaq: FEMY) rose 2.31% in morning trading on Thursday after the company announced that its CEO and Founder, Kathy Lee-Sepsick, has met with several members of Congress to discuss the current women’s healthcare landscape.

In mid-March President Biden released an executive order calling for a $200 million investment in research for women’s health and a coordinated approach from more than 20 federal government agencies. Ms. Lee-Sepsick’s meetings will raise awareness of Femasys and the status of its reproductive products in light of this women’s health initiative by the White House.

“Women’s health remains vastly underserved and underfunded but we are encouraged by the interest our solutions have received during recent meetings with members of Congress. I am proud to be a female-founder and to lead Femasys as we develop revolutionary technologies that provide a continuum of care that are safe, affordable and accessible to women. It is our goal to empower women throughout their reproductive journey by delivering innovative options to meet their needs,” commented Ms. Lee-Sepsick.

Femasys is marketing four commercially-available products including FemaSeed®, FDA-cleared, intratubal insemination, FemVue®, a contrast-generating device, FemCath®, a selective delivery catheter, and FemCerv®, an endocervical tissue sampler. The company also has FemBloc®, a permanent form of birth control in late-stage clinical development.

Femasys recently announced topline data from its FemaSeed pivotal trial, which investigated FemaSeed in women with a variety of infertility factors with the primary efficacy analysis focused on the male factor infertility. FemaSeed demonstrated 24% of women became pregnant after FemaSeed with male factor, and the majority of women who became pregnant did so after the first FemaSeed procedure.

About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. For more information visit www.femasys.com, or follow us on X, Facebook, and LinkedIn.

Share This Article

 

About the Author

Femasys CEO Meets with Members of Congress to Discuss Women’s Healthcare Landscape

Catie Corcoran

Biotech Editor